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Abstract 
Introduction. Pain management and sedation is a priority in neonatal intensive care units. A study was designed with 
the aim of determining current clinical practice as regards sedation and analgesia in neonatal intensive care units in 
Spain, as well as to identify factors associated with the use of sedative and analgesic drugs. 
Methods. A multicenter, observational, longitudinal and prospective study. 
Results. Thirty neonatal units participated and included 468 neonates. Of these, 198 (42.3%) received sedatives or 
analgesics. A total of 19 different drugs were used during the study period, and the most used was fentanyl. Only 
fentanyl, midazolam, morphine and paracetamol were used in at least 20% of the neonates who received sedatives 
and/or analgesics. In infusions, 14 different drug prescriptions were used, with the most frequent being fentanyl and 
the combination of fentanyl and midazolam. The variables associated with receiving sedation and/or analgesia were, 
to have required invasive ventilation (p < .001; OR = 23.79), a CRIB score >3 (p = .023; OR = 2.26), the existence of 
pain evaluation guidelines in the unit (p < .001; OR = 3.82), and a pain leader (p = .034; OR = 2.35). 
Conclusions. Almost half of the neonates admitted to intensive care units receive sedatives or analgesics. There is 
significant variation between Spanish neonatal units as regards sedation and analgesia prescribing. Our results 
provide evidence on the “state of the art”, and could serve as the basis of preparing clinical practice guidelines at a 
national level. 
Resumen 
Introducción. El manejo del dolor y la sedación es una prioridad de los cuidados intensivos neonatales. Se diseñó un 
estudio con el objetivo de determinar la práctica clínica actual en relación con la sedación y la analgesia en unidades 
de cuidados intensivos neonatales en España e identificar factores asociados al uso de fármacos sedantes o 
analgésicos. 
Métodos. Estudio multicéntrico, observacional, longitudinal y prospectivo. 
Resultados. Participaron 30 unidades neonatales y se reclutó a 468 neonatos. De estos, 198 (42.3%) recibieron 
medicación sedante o analgésica. En total, se usaron durante el período de estudio 19 fármacos distintos, de los cuales 
el más utilizado fue el fentanilo. Solo fentanilo, midazolam, morfina y paracetamol se usaron al menos en un 20% de 
los neonatos que recibieron sedación y/o analgesia. Se usaron 14 pautas distintas de fármacos en perfusión, siendo las 
más frecuentes la infusión de fentanilo y la combinación de fentanilo y midazolam. Las variables asociadas a recibir 
sedación y/o analgesia fueron el haber precisado ventilación invasiva (p = <0.001; OR = 23.79), un score de 
CRIB > 3 (p = 0.023; OR = 2.26), la existencia en la unidad de guías de evaluación del dolor (p < 0.001; OR = 3.82) 
y de un líder de dolor (p = 0.034; OR = 2.35). 
Conclusiones. Casi la mitad de los neonatos ingresados en cuidados intensivos recibe medicación sedante y/o 
analgésica. Existe una importante variabilidad entre las unidades neonatales españolas en relación con las pautas de 
sedación y analgesia. Nuestros resultados permiten conocer el “estado del arte” y pueden servir de base para la 
elaboración de guías de práctica clínica a nivel nacional. 
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Introduction 
Pain relief is a basic human right at any age. In new-borns, the inherent difficulty in detecting pain and 
the false belief that neonates lack the necessary physiological pathways for pain transmission have led to 
the historical undertreatment of this age group.1 Nowadays, it is known that new-borns admitted to 
intensive care units (ICU) undergo multiple painful procedures during their stay.2 and 3 Besides, there is 
enough evidence suggesting that untreated pain during the neonatal period can have short-term and long-
term negative consequences.4, 5, 6, 7 and 8 
Currently, there is a wide range of resources for the management of sedation and/or analgesia (S/A), 
including pharmacological and non-pharmacological measures, but, in practice, many guidelines are 
based on experts’ consensus, local protocols or even personal preferences. In an attempt to determine 
common clinical practices regarding pain management in neonatal units, surveys have been published in 
different countries in recent years: France,9 Canada,10 United Kingdom,11 and 12 Australia,13 and 14 Italy,15 
United States,16 Germany, Austria and Switzerland,17 and 18 and Sweden.19 As far as it is known, in Spain 
there is currently no data about the management of S/A in new-borns that allows for critical analysis, or 
that represents a first step towards the preparation of clinical practice guidelines. 
Within the framework of the international multicentre project Europain (www.europainsurvey.eu), a 
specific study for the Spanish sample was designed to determine the current and actual clinical practices 
regarding the use of sedative and analgesic drugs in neonatal ICUs in Spain and the factors associated 
with their use. 
Material and methods 
– Design: Europain-Spain is an observational, longitudinal and prospective study. 
– Selection of units: a list of the neonatal ICUs of the public health care network in Spain was obtained 
from the Spanish Society of Neonatology in 2012. Thirty-four units were invited to participate via e-
mail. These provided comprehensive intensive health care services, including all forms of invasive 
mechanical ventilation. Two units rejected the invitation, one unit failed to respond and another unit 
withdrew from the study upon commencement. Finally, 30 neonatal units from all over the country 
participated (Appendix 1). 
– Inclusion criteria: each of the participating units included all new-borns that were admitted during a 
given month (November 2012) until a corrected age of 44 weeks, and whose legal guardian(s) had 
signed the informed consent form to participate in the study. 
– Data collection: the following information was obtained for each neonate: demographical data; data 
about respiratory assistance devices; use of sedatives, analgesics or muscle relaxants; and drug 
abstinence management. Data collection for each included new-born lasted 28 days or until their 
discharge, transfer to another hospital, or death. Furthermore, unit coordinators provided data about 
local protocols on S/A and general unit statistics. A self-audit was conducted in each participating 
hospital for quality control purposes by a person other than the one responsible for the data entry. 
– Ethical aspects: approval was obtained from the Spanish Agency for Medicines and Healthcare 
Products and from the referent clinical investigation ethics committee, as well as from local 
committees, as required. The informed consent was obtained from the parents and/or legal guardians 
of all the included neonates. 
– Data analysis: a descriptive analysis of the characteristics of the participating units and the included 
patients and their management was conducted, and interval estimates were reported on the main 
findings. Variables associated with the use of S/A were analysed using the square chi test or the 
Fisher's exact test and the Mann–Whitney's test, and odds ratio values and their 95% confidence 
interval were calculated. A multivariate logistic regression model was adjusted to determine the 
associated variables independently of the use of S/A. Given that each unit included a variable number 
of neonates, the adjustment was based on generalised estimating equation models.20 and 21 This 
approach includes the dependency that may exist between data from neonates admitted to the same 
unit and makes it possible to avoid bias associated with classic techniques when the independence 
hypothesis cannot be sustained. A forward modelling strategy was implemented, and variables with a 
value of p < 0.20 in the bivariate analysis were included in the model. For the multivariate analysis, 
units were classified based on the number of annual admissions (above or below 250) and the number 
of annual surgical admissions (above or below 25). Patients were also classified based on a clinical 
risk index for babies (CRIB) score above 3 and equal to or below 3. The statistical analysis was 
carried out using the software SPSS 19.0 for Windows. All tests were conducted based on a bilateral 
approach. Values of p < 0.05 were considered significant. 
Results 
Table 1 describes the characteristics of the 30 participating units. In total, 468 neonates were included. 
Their general characteristics are shown in Table 2. Of the total, 202 neonates (43.2%; 95% CI, 38.5–47.7) 
received invasive mechanical ventilation (MV) during a mean time ± SD of 126.9 ± 173.5 h. 
Table 1. Characteristics of participating units (n = 30). 
Units 
n = 30 
 
  
Existence of local guidelines for pain treatment in 2012, n (%) 20 (66.6) 
Existence of local guidelines for pain assessment in 2012, n (%) 13 (43.3) 
Number of beds  
 Mean ± SD 13.1 ± 7.0 
 Median (range) 12 (2–33) 
Number of admissions/year  
 Mean ± SD 272.9 ± 137.1 
 Median (range) 251 (50–624) 
Number of surgical admissions/year  
 Mean ± SD 42.9 ± 54.1 
 Median (range) 25 (0–222) 
Number of attending physicians  
 Mean ± SD 4.9 ± 3.4 
 Median (range) 4 (2–15) 
 Existence of a medical chief of pain management, n (%) 6 (20) 
 Existence of a nurse chief of pain management, n (%) 4 (13.3) 
 Existence of a pain management team in the unit, n (%) 13 (43.3) 
 24-hour visiting for parents, n (%) 26 (86.6) 
  
 
SD: standard deviation. 
Table 2. Characteristics of neonates included in the study of the total sample and based on the maximum respiratory assistance received during the study period. 
Variable Total n = 468 
Invasive mechanical ventilation n = 
202 (43.2%) 
Non-invasive ventilation n = 149 
(31.8%) 




Gestational age (weeks) 
 Mean ± SD 34.3 ± 4.6 33.4 ± 5.2 33.5 ± 4 36.9 ± 3.5 <0.001 
 Mean (IQ) 34.3 (30.2–38.5) 33.9 (29.1–38) 33.1 (30.2–35.3) 37.4 (33.9–39.8) – 
 24–29, n (%) 107 (22.8) 70 (34.7) 34 (22.8) 3 (2.6) <0.001 
 30–32, n (%) 76 (16.2) 24 (11.9) 37 (24.8) 15 (12.8)  
 33–36, n (%) 115 (24.5) 38 (18.8) 45 (30.2) 32 (27.4)  
 37–42, n (%) 170 (36.3) 70 (34.7) 33 (22.1) 67 (57.3)  
Birth weight (g) 
 Mean ± SD 2.182,8 ± 9764 2.051 ± 1007 1.985 ± 8499 2.663 ± 9197 <0.001 
 Mean (IQ) 2.081 (1390–3025) 2.050 (1.089–2905) 1.880 (1.350–2,425) 2.720 (1,805–3,310) – 
Male, n (%) 256 (54.7) 113 (55.9) 75 (50.3) 68 (58.1) 0.228 
Born in hospital, n (%) 377 (80.5) 143 (70.8) 138 (92.6) 96 (82.1) <0.001 
Age at admission (h) 
 Mean ± SD 64.9 ± 237.3 85.5 ± 309.2 32.7 ± 152.3 70.7 ± 171.4 0.114 
 Mean (IQ) 0.5 (0.23–6.1) 0.5 (0.3–7.3) 0.3 (0.2–1) 0.5 (0.2–48.3) – 
CRIB score      
 Mean ± SD 2.1 ± 3.0 4 ± 3.7 1 ± 1.4 0.6 ± 1.0 <0.001 
 Mean (IQ) 1 (0.0–3.0) 3 (1–6) 0 (0–1) 0 (0–1) – 
Apgar score at 5 min (n = 467) 
 Mean ± SD 8.3 ± 1.8 7.6 ± 2.2 8.8± 1.1 9.2 ± 1.1 <0.001 
 Mean (IQ) 9 (8–10) 8 (6–9) 9 (8–10) 9 (9–10) – 
Already intubated on admission, n (%) 112 (23.9) 112 (55.4) NA NA NA 
Death during the study period, n (%) 21 (3.2) 21 (10.4) 0 (0.0) 0 (0.0) <0.001 
Duration of hospitalisation (days) a 
 Mean ± SD 15.3 ± 10.0 17.0 ± 10.1 16.9 ± 9.8 10.5 ± 8.6 <0.001 
 Mean (IQ) 14 (6–28) 18 (7–28) 17 (8–28) 7 (4–14.5) <0.001 
      
 
The CRIB is an index used for the measurement of severity validated in preterm neonates composed of 6 items collected during the first 12 h of life. The score ranges from 0 to 23, where higher values indicate higher 
severity. 
SD: standard deviation; IQ: interquartile range; NA: not applicable. 
a Data was collected until day No. 28 of hospitalisation. 
 
 
On a global scale, 198 neonates (42.3%; 95% CI, 37.7–46.8) received some kind of sedative or 
analgesic medication. Of these, 16 (8%) received it only in perfusion, 85 (42.9%) only in boluses, and 97 
(48.9%) in perfusion and boluses. 
Of the 202 neonates who received invasive MV, 158 (78.2%; 95% CI, 72.2–84.1) received some kind 
of sedative or analgesic medication. Fig. 1 shows the percentage of neonates who received some kind of 
sedative or analgesic medication and its route of administration, based on the maximum respiratory 




Figure 1. Percentage of neonates (%) who received some kind of sedative or analgesic medication and its route of administration, 
based on the maximum respiratory assistance received during the study period. MV: invasive mechanical ventilation; NIV: non-
invasive ventilation. 
The most commonly used drug was fentanyl, both in perfusion and in boluses, which was used in 
138/468 neonates (29.4%). Table 3 shows the use of most common drugs and their route of administration 
(perfusion or boluses). In total, 19 different drugs were used during the study period. Only fentanyl, 
midazolam, morphine and paracetamol were used, at least, on 20% of neonates who received S/A. Fig. 2 
shows the percentage of patients who received each drug in each participating unit and graphically 
presents the variability between centres regarding the use of these drugs. 
  
Table 3. Percentage of patients treated with different sedative or analgesic drugs during the study period and route of 
administration. The table shows the percentages of the total of patients (n = 468) who received each drug. 
 Total (n = 468) Route of administration 
  In boluses In perfusion 
    
Fentanyl, n (%) 138 (29.4) 111 (23.7) 97 (20.7) 
Midazolam, n (%) 84 (17.9) 75 (16.0) 40 (8.5) 
Paracetamol, n (%) 66 (14.1) 66 (14.1) – 
Morphine, n (%) 40 (8.5) 30 (6.4) 23 (4.9) 
Metamizole, n (%) 16 (3.4) 15 (3.2) 1 (0.2) 
Fenobarbital, n (%) 12 (2.5) 12 (2.5) – 
Clonidine, n (%) 12 (2.5) 8 (1.7) 4 (0.8) 
Propofol, n (%) 10 (2.1) 10 (2.1) – 
Ketamine, n (%) 6 (1.2) 6 (1.2) – 
Remifentanyl, n (%) 5 (1.0) 4 (0.8) 2 (0.4) 
Meperidine, n (%) 4 (0.8) 4 (0.8) – 
Diazepam, n (%) 4 (0.8) 4 (0.8) – 
Penthotal, n (%) 3 (0.6) 3 (0.6) – 
Phenytoin, n (%) 2 (0.4) 2 (0.4) – 
Bupivacaine, n (%) 2 (0.4)a – 2 (0.4) 
Lorazepam, n (%) 1 (0.2) 1 (0.2) – 
Chloral hydrate, n (%) 1 (0.2) 1 (0.2) – 
Levomepromazine, n (%) 1 (0.2) 1 (0.2) – 
Sevoflurane, n (%) 1 (0.2)b 1 (0.2) – 







Figure 2. Graphical representation of the use of the most common drugs in each of the 30 participating units. The horizontal line 
indicates the percentage of each variable in relation to the total sample. The dots represent the percentage of patients who received 
each drug in each of the participating units. 
For the 113 neonates who received sedative or analgesic drugs in continuous perfusion, 14 different 
guidelines were implemented, the most common one being fentanyl infusion (46 neonates, 40.7%) and 
the combination of fentanyl and midazolam (26 neonates, 23%). 
Of the 202 neonates who received invasive MV, 45 (22.2%; 95% CI, 16.2–28.2) received some kind 
of muscle relaxant. Ten neonates received it via continuous perfusion (9 vecuronium, 1 cisatracurium) 
and 41 in boluses (33 vecuronium, 7 succinylcholine, 1 cisatracurium). 
A total of 180 neonates (38.4%; 95% CI, 33.9–42.9) received some kind of oral sweet solution, the 
most common one being sucrose (174 neonates), followed by glucose (6 neonates). 
Abstinence syndrome was diagnosed in 25 of the 165 neonates who had received opioid or 
benzodiazepine (15.2%). In 33 neonates, a clinical scale was used for abstinence assessment, the most 
common being the Finnegan scale (27 neonates, 81.8%), followed by the Lipstiz scale (5 neonates, 
15.1%). A total of 28 neonates received medication for the specific treatment or prevention of abstinence 
symptoms. The most commonly used medication was morphine (14 neonates, 50%), followed by 
clonidine (9 neonates, 32.1%) and methadone (8 neonates, 28.5%). 
Factors associated with sedation and/or analgesia 
Finally, variables related to neonates or to units associated with the use of S/A were analysed (Table 4). 
Based on the multivariate analysis, the associated variables were the following: having received invasive 
MV (p < 0.001; OR = 23.79); a CRIB score > 3 (p = 0.023; OR = 2.26); the existence of local guidelines 
for pain assessment in the unit (p < 0.001; OR = 3.82); and the existence of a medical chief of pain 
management in the unit (p = 0.034; OR = 2.35). However, a gestational age below 33 weeks was 
significantly associated with a lower chance of receiving S/A. The use of pain assessment tools and the 
size of the unit (according to the number of annual admissions or surgical admissions) were not 
associated with the use of S/A ( Table 5). 
 
Table 4. Variables associated with the use of sedative or analgesic medication. Univariate analysis. 
 Use of sedative/analgesic medication 






     
Gestational age   0.004  
 24–29 weeks 51 (47.6) 56 (52.4)  0.9 (0.5–1.4) 
 30–32 weeks 23 (30.2) 53 (69.8)  0.4 (0.2–0.7) 
 33–36 weeks 39 (33.9) 76 (66.1)  0.5 (0.3–0.8) 
 37–42 weeks 85 (50.0) 85 (50.0)  1 
Prematurity (≤36 weeks   0.011  
 Yes 113 (37.9) 185 (62.1)  0.6 (0.4–0.9) 
 No 85 (50.0) 85 (50.0)  1 
Invasive mechanical ventilation   <0.001  
 Yes 158 (78.2) 44 (21.8)  20.2 (12.6–32.5) 
 No 40 (15.0) 226 (85.0)  1 
Use of pain assessment tools   0.001  
 Yes 46 (58.9) 32 (41.1)  2.2 (1.3–3.6) 
 No 152 (38.9) 238 (61.1)  1 
Local guidelines for pain treatment   0.553  
 Yes 140 (43.2) 184 (56.8)  1.1 (0.7–1.6) 
 No 58 (40.2) 86 (59.8)  1 
Local guidelines for pain assessment   <0.001  
 Yes 113 (58.5) 80 (41.5)  3.1 (2.1–4.6) 
 No 85 (30.0) 190 (70.0)  1 
Medical chief of pain management in the unit   0.088  
 Yes 43 (50.5) 42 (49.5)  1.5 (0.9–2.4) 
 No 155 (40.4) 228 (59.6)  1 
Nurse chief of pain management in the unit   0.291  
 Yes 26 (49.0) 27 (51.0)  1.3 (0.7–2.4) 
 No 172 (41.4) 243 (58.6)  1 
Pain management team in the unit   0.524  
 Yes 95 (40.2) 141 (59.8)  0.8 (0.6–1.2) 
 No 98 (43.1) 129 (56.9)  1 
24-h visiting for parents   0.268  
 Yes 184 (43.0) 243 (57.0)  1.6 (0.7–3.3) 
 No 14 (34.1) 27 (65.9)  1 
     
 Mean ± SD Mean ± SD p OR (95% CI)a 
     
Severity (CRIB score) 3.7 ± 3.6 1.0 ± 1.8 <0.001 1.5 (1.3–1.6) 
Number of beds in the unit 16.1 ± 7.5 14.3 ± 7.0 0.008 1.03 (1.01–1.06) 
Number of annual admissions 329.9 ± 138.3 296.4 ± 130.7 0.008 1.01 (1.00–1.01) 
Number of annual surgical admissions 70.9 ± 66.7 53.6 ± 57.5 0.003 1.01 (1.00–1.01) 
     
 
The CRIB is an index used for the measurement of severity validated in preterm neonates composed of 6 items collected during the 
first 12 h of life. The score ranges from 0 to 23, where higher values indicate higher severity. 
SD: standard deviation; OR: odds ratio. 
a OR for each unit of change in the independent variable. 
Table 5. Logistic regression multivariate model using generalised estimating equations of factors associated with the use of sedation 
or analgesia in neonates. 
 B SE p ORa B  
       
Intersection 4.138 0.5806 <0.001    
Gestational age (weeks)       
 24–29 −1.563 0.5439 0.004 0.210 0.072 0.609 
 30–32 −1.126 0.4221 0.008 0.324 0.142 0.742 
 33–36 −0.663 0.3537 0.061 0.515 0.258 1.031 
 37–42    1 (ref)   
Invasive mechanical ventilation 3.183 0.3147 <0.001 24.116 13.016 44.682 
Severity (CRIB score) > 3 0.786 0.3466 0.023 2.195 1.113 4.330 
Local guidelines for pain assessment −1.401 0.3151 <0.001 4.058 2.189 7.526 
Medical chief of pain management in the unit −0.809 0.4049 0.046 2.245 1.015 4.965 
       
 
The CRIB is an index used for the measurement of severity validated in preterm neonates composed of 6 items collected during the 
first 12 h of life. The score ranges from 0 to 23, where higher values indicate higher severity. 
B: regression coefficient; SE: standard error; CI: confidence interval; OR: odds ratio. 
a OR of “yes” compared to “no” when the reference is not indicated. 
Discussion 
As far as it is known, the study is the first prospective, multicentre study for the management of S/A in a sample of 
neonates admitted to Spanish neonatal units. In this study, 42.3% of neonates received some kind of sedative or 
analgesic medication, which reached 78.2% in patients who received invasive MV. Of the total neonates, 31.8% 
received opioids and 17.9% received midazolam. The most commonly used opioid was fentanyl, which was 
administered to 29.4% of the total neonates. 
Almost half of the neonates received some kind of sedative or analgesic drug in this study. On an international 
scale, in 2003, 60.3% of a sample of 151 Dutch neonates received some kind of pharmacological analgesia,3 but this 
percentage was significantly reduced to 36.6% in the same units 8 years after the intensification of non-
pharmacological measures, the implementation of health care measures from the New-born Individualized 
Developmental Care and Assessment Program (NIDCAP) and the development of a treatment protocol based on the 
clinical assessment of pain.22 In the group of neonates with invasive MV, the percentage of S/A amounted to 78.2%. 
The most commonly used drug was fentanyl, followed by midazolam, paracetamol and morphine, which presented 
similarities with the findings obtained in a previous Italian survey.15 MV is a stressful and potentially painful 
technique. Besides, the failure to adapt to or the “struggle” with the respirator may prevent adequate ventilation and 
have a harmful effect.23 International recommendations have been published to promote the use of opioids in 
ventilated neonates7 and their use has been assessed in 2 studies of good methodological quality24 and 25 and in one 
meta-analysis.26 Results ought to be carefully assessed. It has been observed that morphine has a slight effect on pain 
assessment scales during painful procedures, whereas it has no effect on the prevention of neurological damage or 
death.24 and 25 Besides, the use of morphine has been associated with more time to achieve full enteral nutrition in 
premature neonates. However, it should be emphasised that synthetic opioids, such as fentanyl, have not been 
assessed in those aspects and that, particularly, the use of analgesics to relieve neonates’ pain and suffering is, in 
itself, a sufficient reason for their use, even if there is no effect whatsoever on clinical results. 
In Spain, there are several opioids available, but in neonatal units their use is generally limited to fentanyl and 
morphine, and no other opioids can be recommended at the moment. The increased use of fentanyl in Spanish units 
may be explained by the fact that this drug may have some theoretical advantages (strong, rapid action, short 
duration) with an analgesic effect similar to morphine,27 although there are very few randomised studies on this, all of 
which have a small number of patients.28 and 29 
In relation to drugs with mainly sedative action, benzodiazepines are the most commonly used drugs. Midazolam 
is very commonly used (42.4% of neonates who received some kind of S/A), in spite of the absence of proven 
benefits, the concern for its influence on neurodevelopment, in both animals30 and humans,6 and of recent revisions 
advising against its routine use.31 
As in other previous studies, our results indicate a great variability in the S/A guidelines among the 30 
participating units.2 The 19 different drugs used, the 14 different combinations of drugs in perfusion and the 
dispersion of percentages indicating the use of the different drugs expressed in Fig. 2 show the lack of common 
consensus guidelines among Spanish units. This great variability was detected due to bedside data collection of the 
patient. Most probably, the use of these medications may not be detected in survey-like studies. Similarly, Jenkins et 
al., in a prospective study involving 338 paediatric patients (including 39 neonates) from 20 units in the United 
Kingdom, reported the use of 24 different sedative or analgesic drugs.32 Thus, these differences among units hinder 
the comparison of results and the analysis of S/A in our country.  
Oral sweet solutions 
The use of oral sweet solutions during potentially painful procedures has been widely recommended.33 and 34 
Nevertheless, in our study, only 38.4% of neonates received some kind of oral sweet solution (sucrose or glucose). It 
is possible that registration of administration of oral sweet solutions is more lax than that of drugs, although the 
prospective nature of the study should have minimised this potential error. Besides, it is possible that there is still a 
reluctance towards their use because their specific action mechanism is still unknown. Twelve units used sweet 
solutions on more than half of their patients, while in 9 units these solutions were not used on any of the patients 
included in the study. This variability, although also observed with other drugs, is particularly notable in the case of 
oral sweet solutions. 
Local guidelines for pain treatment and pain assessment 
Despite international recommendations regarding the advisability of establishing pain management 
protocols,35 one third of the units declared that they had no written protocol, which is similar to what 
occurred in the study conducted by Mencía et al. in 36 paediatric ICUs in Spain in 2011, in which 64% of 
the units stated that they had a written protocol for sedoanalgesia.36 At an international level, the 
percentage of neonatal units with written protocols ranges from 15%13 to 88%.19 The percentage of our 
sample is similar to that obtained in other related countries.9, 11, 14, 15 and 17 
Factors associated with sedation and/or analgesia 
The multivariate analysis showed that variables associated with an increased use of S/A were term age, MV, severity 
on admission based on the CRIB score, the existence of local guidelines for pain assessment and the existence of a 
medical chief of pain management. MV was the factor most commonly associated with the use of S/A. 
Previous studies have shown pain management differences associated with the size of the units,17 and 19 
the assistance level11 and 12 and the surgical nature.11 In our sample, the number of annual admissions 
(above or below 250) and the number of annual surgical admissions (above or below 25) were not 
associated with the use of S/A. There is very little information about the influence of local guidelines for 
pain management in neonatal units. Some previous studies show significant differences among units with 
written protocols and units without them.17 and 37 In our sample, only the existence of local guidelines for 
pain assessment was independently related to an increased use of S/A, although the implementation of 
pain assessment tools itself was not significantly associated. 
Limitations 
The generalisability of results, which is particularly important in this case, is a very common concern. Most of the 
invited neonatal units participated in our study. These included units from all over the country and a high number of 
consecutive, non-selected patients. Thus, we believe that they faithfully represent the actual situation of S/A in Spain. 
It cannot be ruled out that study participation, as it implies awareness of being observed, modifies practices 
(Hawthorne effect). An attempt to minimise this effect was a relatively lengthy inclusion period (one month) and 
follow-up period (28 days), which ensured personnel rotation. 
Although the initial development of the CRIB scale was conducted in neonates of less than 32 weeks,38 it was 
chosen in this study for severity measurement mainly due to its simplicity and widespread use,39 but also because 
prematurity was the main diagnosis on admission and because of its previous use in similar studies.2 
The doses of used drugs and the non-pharmacological measures implemented for pain management 
were not assessed. The non-collection of this information was aimed at facilitating data collection and at 
making the study viable. In this sense, the decision was successful, but limits the possibility of analysing 
aspects of undoubted interest. 
Conclusions 
Our results make it possible to learn about the actual S/A practices used in Spain and to demonstrate a significant 
variability among the different units. This “state of the art” may lead to the preparation of clinical practice guidelines 
at a national level.40 
Although S/A management is a continuously changing field, and although there are many areas which require 
more study, the creation of working groups and the preparation of guidelines or protocols resulting from the 
consensus reached by different units may lead to the reduction of variability in clinical practice and allow for an 
easier assessment of S/A guidelines in Spain.  
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Appendix 1. Spanish study group Europain.  
Helena Viana, Paloma Lopez Ortego (Hospital Infantil Universitario La Paz, Madrid). Pilar Saenz Gonzalez, Raquel 
Escrig (Hospital Universitari i Politecnic La Fe, Valencia). Eva Bargalló Ailagas, Concepcio Carles (Hospital 
Universitari Josep Trueta, Girona). Laura San Feliciano, Ana Belén Mateo (Hospital Universitario de Salamanca). 
Inés Esteban Diéz, Rosa González Crespo (Hospital San Pedro de Logroño). Ersilia González Carrasco, Isabel de la 
Nogal Tagarro (Hospital Universitario Severo Ochoa, Leganés). María Dolores Elorza Fernández, Nerea Benito 
Guerra (Hospital Universitario de Donostia). Salud Luna Lagares, Pedro Jiménez Parrilla (Hospital Virgen Macarena, 
Sevilla). Francesc Botet, Anna Ciurana, Rebeca Tarjuelo (Hospital Clinic de Barcelona). María José García Borau, 
Nuria Ibáñez (Hospital de la Santa Creu i Sant Pau, Barcelona). Gloria Diáñez Vega (Hospital Universitario Puerta 
del Mar, Cádiz). María Arriaga Redondo (Hospital General Universitario Gregorio Marañón, Madrid). Gloria 
Herranz, Virginia de la Fuente Iglesias (Hospital Clínico San Carlos, Madrid). Amaya Pérez Ocón, Sagrario Santiago 
Aguinaga (Complejo Hospitalario de Navarra). Belén Martín Parra, Antonia Valero Cardona (Hospital General de 
Castellón). María Dolores Sánchez-Redondo, Antonio Arroyos Plana (Hospital Virgen de la Salud, Toledo). Zenaida 
Galve Pradel, Nuria Clavero Montañés (Hospital Universitario Miguel Servet, Zaragoza). María Jesús Ripalda 
Crespo, Raquel Nogales Juárez (Hospital Universitario Príncipe de Asturias, Alcalá de Henares). Aintzane Euba 
Lopez, Sonia Fernández de Retana (Hospital Universitario de Álava). Mar Reyné Vergeli, Raquel Vidal (Hospital 
Sant Joan de Déu, Barcelona). Jose Luis Fernandez-Trisac, María Taboada (Complexo Hospitalario Universitario de 
A Coruña). Aurora Montoro Expósito, Fátima Camba Longueira (Hospital Vall d́Hebron, Barcelona). Gonzalo Solís 
Sánchez (Hospital Universitario Central de Asturias, Oviedo). María Purificación Ventura Faci, Marivi Mallen 
(Hospital Clínico Universitario Lozano Blesa, Zaragoza). Pilar Crespo Suárez, Elvira de Sola (Complexo 
Hospitalario de Pontevedra). Caridad Tapia Collados (Hospital General de Alicante). Isabel de las Cuevas, Beatriz 
Martín (Hospital Universitario Marqués de Valdecilla, Santander). María Luz Couce Pico, Alejandro Pérez 
Muñuzuri, Salomé Quintáns (Complexo Hospitalario Universitario de Santiago). Ana Melgar Bonis, Eugenia Bodas 
(Hospital Universitario 12 de Octubre, Madrid). Ana Concheiro Guisan, Begoña Pérez Costas (Complexo 
Hospitalario Universitario de Vigo). 
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